Overview

Propranolol for Diabetic Retinopathy

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

This study is investigating if the oral beta antagonist propranolol can induce regression of retinal neovascularization associated with proliferative diabetic retinopathy.

Phase:

Phase 1

Details

Lead Sponsor:

University of Wisconsin, Madison

Treatments:

Propranolol